Spatial transcriptomics reveals site-specific cellular and metabolic heterogeneity in bladder carcinoma in situ

Bladder carcinoma in situ (CIS) is a disease characterized by multiple foci and a high risk of progression to muscle-invasive cancer. Current management approaches are often based on genomic profiling of single tumor samples, which may not fully capture the heterogeneity of the tumor and could potentially lead to treatment failure.

This uncertainty is particularly relevant due to the multifocal nature of CIS, which raises questions about the consistency of genomic, immunologic, and microenvironmental features across different anatomical sites within the same patient.

To investigate this issue, researchers performed spatial transcriptomic profiling of CIS tissue samples from four distinct anatomical locations within a single individual. Using unsupervised clustering techniques with marker-based annotation, and integrating metabolic inference, they identified epithelial tumor populations alongside stromal, immune, and smooth muscle compartments.

While some cellular states were found to be consistent across the different sites, their spatial organization and relative abundance varied from one site to another.

Further metabolic analysis revealed that the microenvironments within these different CIS regions were also shaped by the local cellular architecture, resulting in region-specific metabolic activity. These findings demonstrate that both cellular composition and metabolic activity are not uniformly distributed across CIS sites, but rather exhibit spatial structuring.

The researchers conclude that these results indicate a significant degree of intra-patient heterogeneity in CIS that is not captured by profiling a single location. While further validation in larger cohorts is required, these findings suggest that sampling multiple regions of the bladder could potentially improve risk stratification, aid in the development of biomarkers, and enhance the prediction of responses to intravesical therapies.

The implications of these findings could be far-reaching, potentially paving the way for more personalized treatment strategies for bladder carcinoma in situ.